Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis
| Autor: | Rachel M. Knott, Graeme Kay, Kerr H. Matthews, Barbara McKenzie, D. Cairns |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Eye Diseases
Polymers Chemistry Pharmaceutical Cysteamine Bioadhesive Cystinosis Sodium hyaluronate Acrylic Resins Cystine Pharmaceutical Science 02 engineering and technology Pharmacology Cornea 03 medical and health sciences chemistry.chemical_compound Drug Delivery Systems 0302 clinical medicine Nephropathic Cystinosis medicine Animals Humans Hyaluronic Acid Cellulose Apparent viscosity 021001 nanoscience & nanotechnology medicine.disease Solubility chemistry Biochemistry 030221 ophthalmology & optometry Cattle Ophthalmic Solutions Rheology 0210 nano-technology Gels Hydroxyethyl cellulose |
| Zdroj: | International Journal of Pharmaceutics. 515:575-582 |
| ISSN: | 0378-5173 |
| DOI: | 10.1016/j.ijpharm.2016.10.044 |
| Popis: | Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of all organs. It is treated by regular administration of the aminothiol, cysteamine. Corneal crystal deposition is one of the most troublesome complications affecting patients and requires the hourly administration of cysteamine eye drops. In an attempt to reduce this frequency and improve the treatment, the preformulation and evaluation of cysteamine containing gels is reported. Suitability for ophthalmic delivery was determined by analysis of rheology, bioadhesion, dissolution and stability. The results demonstrated that three polymers were suitable for ophthalmic delivery of cysteamine; namely sodium hyaluronate, hydroxyethyl cellulose and carbomer 934. Sodium hyaluronate displayed optimum performance in the preformulation tests, being pseudoplastic (reduction in apparent viscosity under increasing shear rate), bioadhesive, releasing cysteamine over 40min and displaying stability over time. In conclusion these results offer the possibility to formulate cysteamine in an ocular applicable gel formulation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect